CAR-T cell therapy

CAR-T cell therapy has been studied in 40 papers since 2017: 2 observational studies in people, 5 in animals, 33 reviews; 17 in the past year. The newest paper, Nov 10, 2026: “Metabolic Fitness of CAR T-cell Therapy: An Aging Approach”.

Intervention

40 papers study it14 findingsUpdated

Research on it is growing 97% faster than aging research as a whole: 11 papers in the latest year counted

5 new papers in 30 daysSee all 40 papers on CAR-T cell therapy

At a glance

A mouse preprint shows that CAR-T cell therapy reduces cognitive impairment and neuroinflammation in aging, and improves cognitive function and reduces border-associated macrophages in aging and Alzheimer's disease.

14 findings in 9 papers from 2022 to 2026, 4 of them since August 2026

The findings reach mice, none yet in people. 1 lab in 1 country.

None of its findings points the other way.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • Funders: National Cancer Institute and 4 more
  • Humans2
  • Animals5

What did studies of CAR-T cell therapy find?

11

Studies of CAR-T cell therapy measured 11 outcomes, among them cognitive impairment, neuroinflammation and border-associated macrophage.

Cognitive impairment

downin mice1

1 study
  1. CAR-T cell therapy decreases cognitive impairment in mice (aging).

    “either intravenous CAR T cells, which do not infiltrate the brain, or through transplantation of CAR T-treated progenitors is sufficient to reduce neuroinflammation and cognitive impairment”

    Animalsaging

    CAR T cells targeting inflammatory bone marrow progenitors restore cognition in aged mice

    bioRxivPreprint

Neuroinflammation

downin mice1

1 study
  1. CAR-T cell therapy decreases neuroinflammation in mice (aging).

    “targeting of aged inflammatory bone marrow myeloid progenitors through either intravenous CAR T cells, which do not infiltrate the brain, or through transplantation of CAR T-treated progenitors is sufficient to reduce neuroinflammation”

    Animalsaging

    CAR T cells targeting inflammatory bone marrow progenitors restore cognition in aged mice

    bioRxivPreprint

Border-associated macrophage

downin mice1

1 study
  1. CAR-T cell therapy decreases border-associated macrophage in mice (aging and Alzheimer's disease).

    “therapeutic and prophylactic elimination through intrathecal CAR T cell therapy restores cognitive performance”

    Animalsaging and Alzheimer's disease

    CAR T cells targeting inflammatory bone marrow progenitors restore cognition in aged mice

    bioRxivPreprint

Cognitive function

upin mice1

1 study
  1. CAR-T cell therapy improves cognitive function in mice (aging and Alzheimer's disease).

    “intrathecal CAR T cell therapy restores cognitive performance in mouse models of aging and Alzheimer’s disease”

    Animalsaging and Alzheimer's disease

    CAR T cells targeting inflammatory bone marrow progenitors restore cognition in aged mice

    bioRxivPreprint

Tumor burden

downin reviews1−64% tumor regression

1 study
  1. CAR-T cell therapy decreases tumor burden (ultrasound-enabled cancer therapy) (64% tumor regression).

    “achieving 64% tumor regression via CAR T-cell therapy.”

    Reviewultrasound-enabled cancer therapy

    Ultrasound-Mediated CRISPR Delivery and Sonogenetic Modulation for Precision Therapeutics

    Advanced healthcare materials

Fibrotic diseases

downin reviews1

1 study
  1. CAR-T cell therapy decreases fibrotic diseases (preclinical studies).

    “preclinical successes in chronic infections and fibrotic disease”

    Reviewpreclinical studies

    CAR T cell therapy beyond cancer: current status, challenges and future prospects

    Signal transduction and targeted therapy

More on Fibrotic diseases

Fibrosis

downin reviews1

1 study
  1. CAR-T cell therapy decreases fibrosis (preclinical models of fibrosis after senescent cell clearance).

    “resulting in reduced fibrotic burden, improved metabolic parameters, and enhanced tissue function”

    Reviewpreclinical models of fibrosis after senescent cell clearanceanti-uPAR; anti-NKG2D

    Above and beyond senescence and CAR T cell: advances and future perspectives

    Frontiers in immunology

More on Fibrosis

Senescent cells

downin reviews1

1 study
  1. CAR-T cell therapy decreases senescent cells (anti-uPAR or anti-NKG2D CAR T cells in preclinical models).

    “anti-uPAR and anti-NKG2D CAR T cell-based approaches for eliminating senescent cells in preclinical models”

    Reviewanti-uPAR or anti-NKG2D CAR T cells in preclinical modelsanti-uPAR; anti-NKG2D

    Above and beyond senescence and CAR T cell: advances and future perspectives

    Frontiers in immunology

Anti-aging strategy

upin reviews1

1 study
  1. CAR-T cell therapy improves anti-aging strategy in vitro and animal models.

    “the results obtained from in vitro and animal models are encouraging”

    Reviewin vitro and animal models

    Chimeric Antigen Receptor Cell Therapy: Current Status and Its Potential in Aging and Alzheimer's Disease

    International journal of molecular sciences

Autoimmune disease

downin humans1

1 study
  1. CAR-T cell therapy decreases autoimmune disease in severe autoimmune disease.

    “early reports of dramatic clinical responses to CAR-T cells targeting CD19+ B cells in patients with severe autoimmune disease raise the possibility that this approach could lead to durable remissions”

    Reviewin severe autoimmune disease

    Immunotherapy with genetically engineered T cells holds promise for the treatment of nonmalignant diseases in the dog

    Journal of the American Veterinary Medical Association

More on Autoimmune disease

All 11

What is CAR-T cell therapy linked with?

2

Studies link CAR-T cell therapy with 2 measures: T-cell malignancy and neurotoxicity and cytokine release syndrome.

T-cell malignancy

upin humans1

1 study
  1. CAR-T cell therapy is associated with T-cell malignancy in humans.

    “T-cell malignancies derived from CAR-modified cells are exceptionally rare and require direct lineage and vector analysis”

    ReviewMalignancies derived from CAR-modified cells; exceptionally rare and requiring direct lineage and vector analysis

    Second primary malignancies after CAR T-cell therapy: causal attribution, clonal evolution, and risk-adapted surveillance

    Frontiers in immunology

More on T-cell malignancy

Neurotoxicity and cytokine release syndrome

upin humans1

1 study
  1. CAR-T cell therapy raises the risk of neurotoxicity and cytokine release syndrome in humans.

    “the risk of severe or life-threatening toxicities, such as CAR-T induced neurotoxicity and cytokine release syndrome (CRS).”

    Review

    Cell-based medicinal products approved in the European Union: current evidence and perspectives

    Frontiers in pharmacology

More on Neurotoxicity and cytokine release syndrome

What acts on CAR-T cell therapy?

1

Studies name Immunosenescence as acting on CAR-T cell therapy.

Immunosenescence

downin reviews1

1 study
  1. immunosenescence impairs CAR-T cell therapy (elderly patients).

    “immunosenescence, an age-related decline in immune function, poses challenges for CAR T cell therapy in elderly patients”

    Reviewelderly patients

    Above and beyond senescence and CAR T cell: advances and future perspectives

    Frontiers in immunology

Funding

4 grants since 2022

Japan Society for the Promotion of Science¥11.2MNational Institute on Aging$432KNational Cancer Institute$417K

Latest

Dec 2025: 1Jan 2026: 2Feb 2026: 0Mar 2026: 0Apr 2026: 1May 2026: 1Jun 2026: 1Jul 2026: 0Aug 2026: 2Sep 2026: 3Oct 2026: 1Nov 2026: 416 papers in 12 months

See all 40 papers on CAR-T cell therapy